# The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

> **NCT07203729** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 184 (estimated)

## Conditions studied

- HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis

## Interventions

- **DRUG:** Trastuzumab Rezetecan
- **DRUG:** Chemotherapy of Physician's Choice

## Key facts

- **NCT ID:** NCT07203729
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2030-06-15
- **Final completion:** 2030-12-30
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07203729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07203729, "The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07203729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*